Transgene SA - Asset Resilience Ratio

Latest as of June 2023: 7.32%

Transgene SA (TNG) has an Asset Resilience Ratio of 7.32% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Transgene SA (TNG) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€3.63 Million

≈ $4.24 Million USD Cash + Short-term Investments

Total Assets

€49.55 Million

≈ $57.93 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2022)

This chart shows how Transgene SA's Asset Resilience Ratio has changed over time. See TNG total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Transgene SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Transgene SA market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€3.63 Million	7.32%
Total Liquid Assets	€3.63 Million	7.32%

Asset Resilience Insights

Limited Liquidity: Transgene SA maintains only 7.32% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Transgene SA Industry Peers by Asset Resilience Ratio

Compare Transgene SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Transgene SA (2011–2022)

The table below shows the annual Asset Resilience Ratio data for Transgene SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	33.75%	€22.42 Million ≈ $26.21 Million	€66.44 Million ≈ $77.67 Million	-9.12pp
2021-12-31	42.87%	€43.66 Million ≈ $51.04 Million	€101.84 Million ≈ $119.06 Million	+18.21pp
2020-12-31	24.67%	€21.08 Million ≈ $24.64 Million	€85.45 Million ≈ $99.90 Million	-11.73pp
2019-12-31	36.40%	€42.03 Million ≈ $49.14 Million	€115.48 Million ≈ $135.00 Million	+22.56pp
2018-12-31	13.83%	€15.02 Million ≈ $17.55 Million	€108.54 Million ≈ $126.90 Million	-25.58pp
2017-12-31	39.42%	€39.76 Million ≈ $46.49 Million	€100.87 Million ≈ $117.93 Million	-2.35pp
2016-12-31	41.77%	€51.35 Million ≈ $60.04 Million	€122.95 Million ≈ $143.74 Million	+13.65pp
2015-12-31	28.12%	€28.36 Million ≈ $33.16 Million	€100.87 Million ≈ $117.93 Million	-16.17pp
2014-12-31	44.29%	€62.42 Million ≈ $72.98 Million	€140.95 Million ≈ $164.79 Million	+10.34pp
2013-12-31	33.95%	€42.72 Million ≈ $49.95 Million	€125.85 Million ≈ $147.13 Million	-20.13pp
2012-12-31	54.08%	€86.78 Million ≈ $101.45 Million	€160.46 Million ≈ $187.60 Million	-17.09pp
2011-12-31	71.17%	€137.77 Million ≈ $161.07 Million	€193.58 Million ≈ $226.32 Million	--

pp = percentage points

About Transgene SA

PA:TNG France Biotechnology

Market Cap

$238.89 Million

€204.33 Million EUR

Market Cap Rank

#15994 Global

#235 in France

Share Price

€0.75

Change (1 day)

+0.13%

52-Week Range

€0.56 - €1.48

All Time High

€3.72